Rivaxo 20gm Tablet


Pack Size:                 10’s

Composition :        Rivaroxaban

Pharmaceutical form :  tablet

Brand Name: GETZ



Rivaxo 20gm Tablet

Rivaxo 20gm Tablet (Rivaroxaban) is a highly selective direct Factor Xa inhibitor with oral bioavailability.Rivaxo 20gm Tablet is chemically designated as 5-Chloro-N- ({(5S)-2-oxo-3- [4-(3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl) -2-thiophene-carboxamide. Rivaxo 20gm Tablet molecular formula is C19H18ClN3O5S. Hemorrhagic risk As with other anticoagulants, patients taking rivaroxaban are to be carefully observed for signs of bleeding.Rivaxo 20gm Tablet is recommended to be used with caution in conditions with increased risk of hemorrhage. Rivaxo 20gm Tablet administration should be discontinued if severe hemorrhage occurs. Renal impairmentRivaxo 20gm Tablet is to be used with caution in patients with creatinine clearance 15 – 29 ml/min. Use is not recommended in patients with creatinine clearance.

side effects of this drug as :Anemia (incl. respective laboratory parameters), dizziness, headache, eye hemorrhage (incl. conjunctival hemorrhage),


Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation Rivaxo (Rivaroxaban) is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. • Treatment of Deep Vein Thrombosis Rivaxo (Rivaroxaban) is indicated for the treatment of deep vein thrombosis (DVT). • Treatment of Pulmonary Embolism Rivaxo (Rivaroxaban) is indicated for the treatment of pulmonary embolism (PE).

Side effect :

Anemia (incl. respective laboratory parameters), dizziness, headache, eye hemorrhage (incl. conjunctival hemorrhage), hypotension, hematoma, epistaxis, hemoptysis, gingival bleeding, gastrointestinal tract hemorrhage (incl. rectal hemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation, diarrhea, vomiting, pruritus

When not use :

Hypersensitivity toRivaxo 20gm Tablet or to any of the excipient of product. • Active clinically significant bleeding. • Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities


There are no reviews yet.

Be the first to review “Rivaxo 20gm Tablet”

Your email address will not be published. Required fields are marked *